[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 24 of about 24
1. Hefny AF, Bashir MO, Joshi S, Branicki FJ, Abu-Zidan FM: Stromal sarcoma of the breast: a case report. Asian J Surg; 2004 Oct;27(4):339-41
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stromal sarcoma of the breast: a case report.
  • We report a case of a 36-year-old lady who presented with a huge fungating tumour that involved the entire right breast.
  • The tumour was diagnosed histologically as undifferentiated primary stromal tumour of the breast with axillary lymph node metastasis.
  • Stromal sarcomas of the breast lack epithelial participation, and diagnosis of these tumours can be difficult.
  • Surgery offers the best therapeutic option.
  • Adjuvant radiotherapy is not very beneficial, while chemotherapy has, to date, no established role in the management of this disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15564192.001).
  • [ISSN] 1015-9584
  • [Journal-full-title] Asian journal of surgery
  • [ISO-abbreviation] Asian J Surg
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  •  go-up   go-down


2. Grenier J, Delbaldo C, Zelek L, Piedbois P: [Phyllodes tumors and breast sarcomas: a review]. Bull Cancer; 2010 Oct;97(10):1197-207
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Phyllodes tumors and breast sarcomas: a review].
  • Phyllodes tumors and sarcomas of the breast are non-epithelial tumors of the breast.
  • The differential diagnosis with a very proliferant fibroadenoma may be difficult.
  • Histological sub-type, type of surgery (definitive or not) and stromal proliferation determine the prognosis.
  • Surgery (often radical) is the standard treatment.
  • Breast sarcomas are even rarer.
  • All histological types exist with a predominance of histiofibrocytome type tumors.
  • Among the various sub-types, angiosarcoma is characterized by a high risk of occurrence in irradiated fields and by a poor prognosis with a high risk of lung metastases.
  • The treatment is mostly based on mastectomy without lymph node dissection given the exceptional flooding axillary.
  • In some situations, a conservative treatment can be discussed, based on tumor size, grade and volume of the breast.
  • Systemic chemotherapy is not a standard but should be discussed in the forms at high risk of relapse (like angiosarcoma).
  • [MeSH-major] Breast Neoplasms / pathology. Phyllodes Tumor / pathology. Sarcoma / pathology
  • [MeSH-minor] Female. Hemangiosarcoma / pathology. Hemangiosarcoma / secondary. Hemangiosarcoma / therapy. Humans. Neoplasm Recurrence, Local. Prognosis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20855241.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  •  go-up   go-down


3. André T, Wislez M, Goncalves A, de La Motte Rouge T, Blay JY, Massard C, Bay JO, comité de rédaction du Bulletin du Cancer: [Following communications made at American Society of Clinical Oncology 2010, what will change our practice? The point of view of the editorial board of Bulletin du Cancer]. Bull Cancer; 2010 Dec;97(12):1551-62

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Suite aux communications faites au congrès de l'American Society of Clinical Oncology 2010, qu'est ce qui va changer nos pratiques ? Le point de vue du comité de rédaction du Bulletin du cancer.
  • Best understanding of biological mechanisms and new molecules to inhibit targets allow in certain case, to use therapeutic targeting in the true sense.
  • In Advanced non-small cell lung cancer, myeloma and advanced lymphoma, maintenance therapy by monoclonal anti-body or inhibitors of tyrosines kinases showed the proof of their effectiveness.
  • Biological personalization of cancer treatments is on the road run but the road is still long.
  • [MeSH-major] Medical Oncology / standards. Neoplasms / therapy. Practice Patterns, Physicians' / standards. Societies, Medical / standards
  • [MeSH-minor] Breast Neoplasms / therapy. Digestive System Neoplasms / therapy. Female. Gastrointestinal Stromal Tumors / drug therapy. Genital Neoplasms, Female / drug therapy. Hematologic Neoplasms / therapy. Humans. Lung Neoplasms / drug therapy. Male. Melanoma / drug therapy. Prostatic Neoplasms / drug therapy. Sarcoma / drug therapy. Testicular Neoplasms / drug therapy. Thyroid Neoplasms / drug therapy. United States

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21220230.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


Advertisement
4. Sesti F, Patrizi L, Ermini B, Palmieri G, Orlandi A, Piccione E: High-grade endometrial stromal sarcoma after tamoxifen therapy for breast cancer. Gynecol Obstet Invest; 2005;60(2):117-20
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-grade endometrial stromal sarcoma after tamoxifen therapy for breast cancer.
  • A case of high-grade endometrial stromal sarcoma, confined into an intrauterine polypoid growth, in a woman with a history of breast cancer who was treated with adjuvant tamoxifen.
  • Based on the findings, a high-grade endometrial stromal sarcoma was diagnosed.
  • In deciding if tamoxifen therapy is warranted, all potentially life-threatening adverse events associated with tamoxifen should be considered, including endometrial adenocarcinoma or uterine sarcoma.
  • [MeSH-major] Antineoplastic Agents, Hormonal / adverse effects. Breast Neoplasms / drug therapy. Neoplasms, Second Primary / chemically induced. Sarcoma, Endometrial Stromal / chemically induced. Tamoxifen / adverse effects. Uterine Neoplasms / chemically induced


5. Tochika N, Kumon M, Ogawa Y, Sugimoto T, Araki K: Stromal sarcoma of the breast with lung metastasis successfully treated by radiotherapy: report of a case. Surg Today; 2000;30(3):282-5
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stromal sarcoma of the breast with lung metastasis successfully treated by radiotherapy: report of a case.
  • We report herein the case of a 42-year-old woman in whom a solitary lung metastasis from stromal sarcoma of the breast was effectively treated by radiotherapy.
  • The original breast tumor had been extirpated in a local hospital, and she was subsequently referred to our outpatient clinic for nonsurgical treatment.
  • Pathological examination of the breast tumor had confirmed a diagnosis of stromal sarcoma.
  • Radiation and systemic chemotherapy for the remnant disease were administered at our hospital; however, 8 months later, local recurrence and a solitary lung metastasis were recognized on a chest X-ray.
  • A second lumpectomy of the recurrent breast tumor along with radiation for the lung metastasis and systemic chemotherapy were performed.
  • This case serves to demonstrate the effectiveness of radiotherapy for the treatment of lung metastasis from stromal sarcoma of the breast.
  • [MeSH-major] Breast Neoplasms / pathology. Lung Neoplasms / radiotherapy. Lung Neoplasms / secondary. Sarcoma / radiotherapy. Sarcoma / secondary
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Mastectomy, Segmental. Mesenchymoma / pathology. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Breast Cancer. 1994 Jul 30;1(1):61-64 [11091509.001]
  • [Cites] Cancer. 1962 Mar-Apr;15:418-24 [13867580.001]
  • [Cites] Mo Med. 1972 Aug;69(8):672-4 passim [5049192.001]
  • [Cites] Surgery. 1994 Sep;116(3):505-9 [8079181.001]
  • (PMID = 10752784.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


6. Hassan S, Adari G: Primary breast sarcoma: case report. East Afr Med J; 2004 Jul;81(7):375-7
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary breast sarcoma: case report.
  • Primary breast sarcoma is a rare entity occurring in 0.5% of women with breast malignancy.
  • Like in breast carcinoma, delay in its diagnosis has important clinical and treatment implications.
  • The subject of this report presented at our breast unit with advanced breast lesion months after she noticed a small lump in her right breast.
  • She had no clear diagnosis despite several consultations, in-patient treatments at two facilities in the city, breast ultrasonography, breast mammography and three fine needle aspiration cytology (FNAC) examinations.
  • Histology following wide excision confirmed high-grade primary stromal breast sarcoma.
  • She required adjuvant combination chemotherapy.
  • A combination of diagnostic failures and patient fault caused delay in subject's treatment.
  • Lesion progression during delay which influenced the pattern of physical morbidity, tumour prognosis and need for adjuvant treatment.
  • Embracing the concept of breast care in dedicated breast units may minimise such treatment delays.
  • [MeSH-major] Breast Neoplasms / diagnosis. Sarcoma / diagnosis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15490711.001).
  • [ISSN] 0012-835X
  • [Journal-full-title] East African medical journal
  • [ISO-abbreviation] East Afr Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Kenya
  •  go-up   go-down


7. Bhattacharjee PK, Ghosh S, Choudhury T, Mitra SK, Banerjee S: Stromal sarcoma of breast: a case report. J Indian Med Assoc; 2000 Apr;98(4):189-90
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stromal sarcoma of breast: a case report.
  • A 34 years unmarried female was admitted with an ulcerated foul smelling growth in her right breast.
  • On examination the fungating mass measured 17.5 cm x 15 cm in central and lower part of right breast involving the nipple and areola.
  • The ulcer was covered with slough and rest part of the breast appeared bosselated.
  • Her Hb was 4 g/dl and incision biopsy from the margin of the tumour showed histology of sarcoma.
  • Histopathological examination confirmed it was a case of stromal sarcoma of breast.
  • Chemotherapy was started with vincristine, adriamycin and cylophosphamide.
  • [MeSH-major] Breast Neoplasms / pathology. Sarcoma / pathology
  • [MeSH-minor] Adult. Breast / pathology. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Mastectomy, Simple

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11016187.001).
  • [ISSN] 0019-5847
  • [Journal-full-title] Journal of the Indian Medical Association
  • [ISO-abbreviation] J Indian Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] INDIA
  •  go-up   go-down


8. Boardman CH, Webb MJ, Jefferies JA: Low-grade endometrial stromal sarcoma of the ectocervix after therapy for breast cancer. Gynecol Oncol; 2000 Oct;79(1):120-3
Hazardous Substances Data Bank. GOSERELIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-grade endometrial stromal sarcoma of the ectocervix after therapy for breast cancer.
  • OBJECTIVE: Low-grade endometrial stromal sarcoma is an uncommon, indolent uterine sarcoma that can arise in extrauterine locations.
  • The objective of this study was to report on a previously unpublished site of origin for a low-grade endometrial stromal sarcoma.
  • METHODS: A case of a low-grade endometrial stromal sarcoma arising in the ectocervix after goserelin hormonal therapy for breast cancer was studied.
  • RESULTS: Low-grade endometrial stromal sarcoma can arise in the ectocervix even in the absence of endometriosis.
  • CONCLUSION: Low-grade endometrial stromal sarcoma should be included in the differential diagnosis of sarcomas of the ectocervix.
  • [MeSH-major] Endometrial Neoplasms / pathology. Neoplasms, Second Primary / pathology. Sarcoma, Endometrial Stromal / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Agents, Hormonal / adverse effects. Antineoplastic Agents, Hormonal / therapeutic use. Breast Neoplasms / drug therapy. Female. Goserelin / adverse effects. Goserelin / therapeutic use. Humans. Middle Aged


9. Pandey M, Mathew A, Abraham EK, Rajan B: Primary sarcoma of the breast. J Surg Oncol; 2004 Sep 1;87(3):121-5
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary sarcoma of the breast.
  • BACKGROUND AND OBJECTIVES: Primary sarcoma occurring in breast is rare and comprises 0.5-1% of all breast neoplasm.
  • Majority of the series include both stromal and cystosarcoma phyllodes, only a few hundred cases of sarcomas other then cystosarcoma are reported.
  • PATIENTS AND METHODS: We carried out a retrospective analysis of 19 patients with primary sarcoma of the breast treated between 1982 and 2002.
  • There were eight cases of angiosarcoma, four cases of spindle cell sarcoma, two each of pleomorphic sarcoma and stromal sarcoma, and one each of malignant fibrous histiocytoma, embryonal rhabdomyosarcoma, and sarcoma (NOS).
  • Two patients received chemotherapy.
  • After a mean follow-up time of 34.5 months (median 25 months), eight patients failed.
  • Failure was local in five, opposite breast in one, and both local and distant in two.
  • CONCLUSIONS: Primary sarcomas of the breast are aggressive tumors.
  • Surgical treatment should consist of at least simple mastectomy.
  • [MeSH-major] Breast Neoplasms / surgery. Mastectomy. Sarcoma / surgery
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Child. Disease-Free Survival. Female. Hemangiosarcoma / drug therapy. Hemangiosarcoma / radiotherapy. Hemangiosarcoma / surgery. Histiocytoma, Benign Fibrous / drug therapy. Histiocytoma, Benign Fibrous / radiotherapy. Histiocytoma, Benign Fibrous / surgery. Humans. Middle Aged. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Rhabdomyosarcoma / drug therapy. Rhabdomyosarcoma / radiotherapy. Rhabdomyosarcoma / surgery. Survival Analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mastectomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Wiley-Liss, Inc.
  • [CommentIn] J Surg Oncol. 2004 Oct 1;88(1):50-1 [15384090.001]
  • (PMID = 15334638.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Leiser AL, Hamid AM, Blanchard R: Recurrence of prolactin-producing endometrial stromal sarcoma with sex-cord stromal component treated with progestin and aromatase inhibitor. Gynecol Oncol; 2004 Aug;94(2):567-71
Hazardous Substances Data Bank. ANASTROZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence of prolactin-producing endometrial stromal sarcoma with sex-cord stromal component treated with progestin and aromatase inhibitor.
  • INTRODUCTION: Endometrial stromal tumors with sex-cord-like elements are relatively rare.
  • CASE REPORT: A 48-year-old woman was diagnosed with Stage I endometrial stroma sarcoma with sex-cord component at the time of hysterectomy for presumed fibroid uterus.
  • One and a half years later, she presented with recurrent disease in the abdomen associated with breast tenderness, galactorrhea, and an elevated prolactin level.
  • She received three cycles of BEP (Bleomycin, Etoposide, Cisplatin) with partial response and followed by an optimal debulking procedure.
  • Disease was progressive through three cycles of Docetaxel and Gemcitabine therapy, but had an objective response to treatment with anastrozole and megestrol acetate.
  • DISCUSSION: Endometrial stromal sarcoma with sex-cord stromal component may be hormonally functional.
  • Similarly to pure endometrial stromal sarcomas, they may respond to hormonal treatment, and further study is warranted.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Endometrial Neoplasms / drug therapy. Enzyme Inhibitors / therapeutic use. Megestrol Acetate / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Nitriles / therapeutic use. Sarcoma, Endometrial Stromal / drug therapy. Triazoles / therapeutic use
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Aromatase Inhibitors. Female. Humans. Middle Aged. Progestins / antagonists & inhibitors. Prolactin / biosynthesis

  • Genetic Alliance. consumer health - Endometrial Stromal Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15297205.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Aromatase Inhibitors; 0 / Enzyme Inhibitors; 0 / Nitriles; 0 / Progestins; 0 / Triazoles; 2Z07MYW1AZ / anastrozole; 9002-62-4 / Prolactin; TJ2M0FR8ES / Megestrol Acetate
  •  go-up   go-down


11. Saga Y, Ohwada M, Kohno T, Takayashiki N, Suzuki M: High-grade endometrial stromal sarcoma after treatment with tamoxifen in a patient treated for breast cancer. Int J Gynecol Cancer; 2003 Sep-Oct;13(5):690-2
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-grade endometrial stromal sarcoma after treatment with tamoxifen in a patient treated for breast cancer.
  • Tamoxifen has been widely used in breast cancer treatment.
  • In recent years, the occurrence of uterine malignancies in patients receiving long-term tamoxifen therapy has attracted attention.
  • Most of these malignancies are endometrial adenocarcinomas, but low-grade endometrial stromal sarcomas have occasionally been reported.
  • Here we report a woman who developed a high-grade endometrial stromal sarcoma after receiving postmastectomy tamoxifen therapy.
  • At age 51, she was diagnosed with endometrial stromal sarcoma, for which a radical hysterectomy was performed.
  • High-grade endometrial stromal sarcoma was diagnosed by postoperative histologic examination.
  • Immunostaining for the estrogen receptor was negative in sarcoma cells, but positive in the residual endometrial epithelium and the nucleus of adjacent stromal cells within the tumor.
  • [MeSH-major] Antineoplastic Agents, Hormonal / adverse effects. Breast Neoplasms / drug therapy. Endometrial Neoplasms / diagnosis. Sarcoma, Endometrial Stromal / diagnosis. Tamoxifen / adverse effects
  • [MeSH-minor] Administration, Oral. Diagnosis, Differential. Female. Humans. Middle Aged. Survivors

  • Genetic Alliance. consumer health - Endometrial Stromal Sarcoma.
  • Genetic Alliance. consumer health - Endometrial cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14675357.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


12. Liao JB, Lin JY: Estrogen receptor expression in an endometrial stromal sarcoma after tamoxifen therapy. Eur J Gynaecol Oncol; 2001;22(6):417-9
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Estrogen receptor expression in an endometrial stromal sarcoma after tamoxifen therapy.
  • INTRODUCTION: Several cases of low-grade endometrial stromal sarcomas in women with breast cancer have been reported to be associated with tamoxifen therapy.
  • CASE: A low-grade endometrial stromal sarcoma in a woman with a history of breast cancer treated with adjuvant tamoxifen is presented.
  • CONCLUSION: The absence of estrogen receptor expression suggests that endometrial stromal sarcomas are not necessarily caused by the estrogenic properties of tamoxifen.
  • [MeSH-major] Endometrial Neoplasms / drug therapy. Estrogen Antagonists / therapeutic use. Receptors, Estrogen / analysis. Sarcoma / drug therapy. Tamoxifen / therapeutic use

  • Genetic Alliance. consumer health - Endometrial Stromal Sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11874071.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Estrogen Antagonists; 0 / Receptors, Estrogen; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


13. Moreno-Vega A, Chavarría N, Rubio J, Villandiego I, Estepa R, Gordon M, Salvador J, Jimenez E: Primary breast sarcoma: Clinical and retrospective analysis of cases from Jerez General Hospital, Spain. J Clin Oncol; 2009 May 20;27(15_suppl):e21526

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary breast sarcoma: Clinical and retrospective analysis of cases from Jerez General Hospital, Spain.
  • : e21526 Background: Primary sarcomas of the breast (PBS) are a heterogeneous group of tumors from stromal breast, infrequent (0.1% of BC).
  • Diagnosis and treatment is unclear.
  • Heterogeneous chemotherapy/radiotherapy schedules was evaluated .
  • RESULTS: Seven cases of PBS (1 male/6 female) were reviewed, from 790 BC diagnosed (0.8%): 2 angiosarcomas (AS), 1 malignant fibrous histiocytoma, 2 undifferentiated, one osteoclastic and other spindle-cell sarcoma.
  • Adjuvant therapy was radiation 57.14% pts; and chemotherapy (doxorubicin 4/liposomal doxorubicin 2 pts) in recurrence.
  • CONCLUSIONS: PBS are rare and difficult diagnosis tumors.
  • There are few series published, without prospective studies to evaluate an adequate therapy, diagnosis and valuable prognostic factors.
  • Our incidence was high, but the independent pathology analysis confirmed all histopathological diagnosis.
  • This review included novel IHC and IRM images, considered necessary for diagnosis and personalized treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963456.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Guerrero MA, Ballard BR, Grau AM: Malignant phyllodes tumor of the breast: review of the literature and case report of stromal overgrowth. Surg Oncol; 2003 Jul;12(1):27-37
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant phyllodes tumor of the breast: review of the literature and case report of stromal overgrowth.
  • Cystosarcoma phyllodes constitutes only 0.3-0.9% of all breast tumors.
  • The term "sarcoma" was initially used because of its fleshy appearance, a more modern term is Phyllodes tumor (PT).
  • The microscopic appearance of PT is that of epithelial elements and connective tissue stroma.
  • Wide local excision with 2 cm margins is the treatment of choice.
  • There is no proven benefit of radiation or chemotherapy, although radiotherapy may be useful in selected cases.
  • We present a case of a sarcomatous overgrowth in a malignant phyllodes tumor involving multiple histologic types.
  • [MeSH-major] Breast Neoplasms / surgery. Phyllodes Tumor / surgery
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Humans. Treatment Outcome

  • Genetic Alliance. consumer health - Phyllodes Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12689668.001).
  • [ISSN] 0960-7404
  • [Journal-full-title] Surgical oncology
  • [ISO-abbreviation] Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 56
  •  go-up   go-down


15. Alabassi A, Fentiman IS: Sarcomas of the breast. Int J Clin Pract; 2003 Dec;57(10):886-9
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sarcomas of the breast.
  • Breast sarcomas are rare lesions that can be derived from any of the mammary stromal cells.
  • For all the sarcomas spread is haematogenous rather than lymphatic and treatment is based on wide surgical clearance without axillary surgery.
  • Angiosarcoma is a rare consequence of skin irradiation as part of breast conservation therapy.
  • Radiotherapy is not of value but chemotherapy can be used to palliate women with metastatic disease.
  • [MeSH-major] Breast Neoplasms / pathology. Sarcoma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Female. Humans. Mastectomy / methods. Middle Aged

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14712891.001).
  • [ISSN] 1368-5031
  • [Journal-full-title] International journal of clinical practice
  • [ISO-abbreviation] Int. J. Clin. Pract.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 32
  •  go-up   go-down


16. Blanchard DK, Reynolds CA, Grant CS, Donohue JH: Primary nonphylloides breast sarcomas. Am J Surg; 2003 Oct;186(4):359-61
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary nonphylloides breast sarcomas.
  • BACKGROUND: The prevalence of primary breast sarcoma is low, occurring in fewer than 1% of women with breast malignancies.
  • The purpose of this study was to examine the presentation, treatment, and prognosis of patients presenting with these neoplasms.
  • METHODS: This was a retrospective review of patients with a primary breast sarcoma treated at Mayo Clinic, Rochester, Minnesota, between 1975 and 2001.
  • RESULTS: Of the 55 patients, 17 had breast-conserving therapy and 38 women had mastectomy.
  • The types of sarcoma included angiosarcoma (18), malignant fibrous histiocytoma (11), stromal sarcoma (8), liposarcoma (4), leiomyosarcoma (4), dermatofibrosarcoma protuberans (4), osteosarcoma (3), fibrosarcoma (2), and rhabdomyosarcoma (1).
  • Twenty-nine of 53 patients (55%) developed recurrent sarcoma, and 23 patients (43%) died of their disease.
  • Overall median survival of patients with breast sarcoma was 58 months.
  • Patients with angiosarcoma had a poorer outcome than other sarcoma patients.
  • Twelve of 18 patients (67%) died of angiosarcoma, compared with 11 of 32 patients (34%) of all other sarcoma patients combined.
  • Of 34 patients who did not receive adjuvant chemotherapy or radiation, 13 died of their disease (38%), as compared with 10 of 16 patients (63%) who did receive adjuvant therapy.
  • CONCLUSIONS: While primary nonphylloides breast sarcomas are rare tumors, their treatment and prognosis are poor.
  • Adjuvant chemotherapy and radiation did not improve survival in this report.
  • Surgical extirpation remains the only effective treatment.
  • [MeSH-major] Breast Neoplasms. Sarcoma

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14553850.001).
  • [ISSN] 0002-9610
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Reynoso D, Subbiah V, Trent JC, Guadagnolo BA, Lazar AJ, Benjamin R, Pollock RE, Ludwig JA: Neoadjuvant treatment of soft-tissue sarcoma: a multimodality approach. J Surg Oncol; 2010 Mar 15;101(4):327-33
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant treatment of soft-tissue sarcoma: a multimodality approach.
  • Unlike epithelial cancers that are both more homogeneous and easily categorized by their respective tissues of origin (e.g., breast or lung cancer), sarcomas represent a diverse class of molecularly distinct bone and soft-tissue mesenchymal neoplasms of more than 50 subtypes.
  • This diversity, as well as the relative rarity of sarcomas as a whole, has presented challenges in conducting prospective randomized clinical trials to assess the value of neoadjuvant chemotherapy for any given subtype.
  • Most clinical trials and meta-analyses have neglected the phenotypic and molecular heterogeneity differentiating one sarcoma subtype from another in favor of a simplified grouping that ensures timely trial completion.
  • As the success of treating gastrointestinal stromal tumors (GISTs) with imatinib demonstrates, a decision to provide neoadjuvant chemotherapy must take into consideration both the subtype being treated and the effect such treatment would be expected to exert upon that subtype.
  • [MeSH-major] Sarcoma / therapy
  • [MeSH-minor] Antineoplastic Agents / administration & dosage. Humans. Neoadjuvant Therapy. Neoplasm Staging. Patient Selection. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20187067.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 44
  •  go-up   go-down


18. Le Bouëdec G, Auvray H, Curé H, de Latour M, Penault-Llorca F, Dauplat J: [Uterine sarcoma in patients receiving tamoxifen therapy. Apropos of 2 cases]. Rev Med Interne; 2001 Sep;22(9):881-5
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Uterine sarcoma in patients receiving tamoxifen therapy. Apropos of 2 cases].
  • [Transliterated title] Sarcome utérin survenant au cours d'une hormonothérapie par tamoxifène. A propos de deux cas.
  • Concern has been raised about prolonged tamoxifen treatment and subsequent occurrence of endometrial adenocarcinoma; subsequent attention has been drawn through high risk histologic subtypes including poorly differentiated patterns and uterine sarcomas.
  • EXEGESIS: We report two cases of uterine sarcoma arising in postmenopausal women taking tamoxifen, 20 mg daily during 38 and 42 months, for breast carcinoma: one leiomyosarcoma and one endometrial stromal sarcoma; both cases were asymptomatic and detected by pelvic sonography.
  • CONCLUSION: Further studies will be required to establish if there is a relationship between long term tamoxifen exposure and highly aggressive types of cancer of the uterine corpus exhibiting adverse histologic features such as uterine sarcomas.

  • Genetic Alliance. consumer health - Uterine sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11599191.001).
  • [ISSN] 0248-8663
  • [Journal-full-title] La Revue de medecine interne
  • [ISO-abbreviation] Rev Med Interne
  • [Language] FRE
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Estrogen Antagonists; 0 / Selective Estrogen Receptor Modulators; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


19. Ohri A, Jetly D, Shukla K, Bansal R: Cytological grading of breast neoplasia and its correlation with histological grading. Indian J Pathol Microbiol; 2006 Apr;49(2):208-13
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytological grading of breast neoplasia and its correlation with histological grading.
  • Cytological grading of breast cancer is not well established despite histological grading having gained a strong foothold.
  • In our study we have analyzed 50 cases of breast carcinoma which included invasive ductal carcinoma, invasive lobular carcinoma, mucinous carcinoma, stromal sarcoma, apocrine carcinoma, papillary carcinoma.
  • Simplified Black grading system has been recommended for cytological grading of breast neoplasia because of its lucidity and its reproducibility.
  • Cytological grading of breast neoplasia is important for neo adjuvant chemotherapy and also for predicting the prognosis of the patient on FNAC alone.
  • [MeSH-major] Breast Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16933716.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] India
  •  go-up   go-down


20. Confavreux C, Lurkin A, Mitton N, Blondet R, Saba C, Ranchère D, Sunyach MP, Thiesse P, Biron P, Blay JY, Ray-Coquard I: Sarcomas and malignant phyllodes tumours of the breast--a retrospective study. Eur J Cancer; 2006 Nov;42(16):2715-21
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sarcomas and malignant phyllodes tumours of the breast--a retrospective study.
  • BACKGROUND: Although most breast cancers are adenocarcinomas of the mammary gland, primary breast sarcomas may also arise from mammary gland mesenchymal tissue.
  • The annual incidence of primary breast sarcoma is low and has been estimated at 45 new cases per 10 million women.
  • Phyllodes tumours represent a specific subset of these breast soft tissue tumours.
  • They are composed of a connective tissue stroma and epithelial elements.
  • Pathological presentation ranges from grade I to malignant phyllodes tumours (grade III) where the stromal component clearly exhibits a sarcoma pattern.
  • MATERIALS AND METHODS: SAPHYR (SArcoma and PHYllode Retrospective) is a retrospective study of the experience of Leon Bérard Cancer Centre (Lyon, France) from 1966 to August 2004.
  • SAPHYR aims to describe the characteristics of primary breast sarcomas and to define potential survival factors to be evaluated in future prospective studies.
  • No survival difference was found between malignant phyllodes (grade III) and other primary breast sarcomas (angiosarcomas excluded).
  • Histology revealed three significantly (p=0.0003) different prognostic groups: phyllodes grade I and II (DFS=57%), angiosarcomas (DFS=7%) and phyllodes grade III and other primary breast sarcomas (DFS=45%).
  • DISCUSSION: Phyllodes tumours and primary breast sarcomas are totally different from epithelial breast cancers and should be considered as a distinct group of rare tumours.
  • The first goal of treatment is to achieve negative margins (R0).
  • We propose to treat the patients according to the clinical practice guidelines in use for soft tissue sarcomas and address them to a reference centre for sarcoma.
  • Treating rare tumours in the same place should permit us to standardise pathological data and to include patients into multicentric radiotherapy or chemotherapy protocols to improve overall survival.
  • [MeSH-major] Breast Neoplasms. Phyllodes Tumor. Sarcoma

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17023158.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


21. Gadducci A, Cosio S, Genazzani AR: Use of estrogen antagonists and aromatase inhibitors in breast cancer and hormonally sensitive tumors of the uterine body. Curr Opin Investig Drugs; 2004 Oct;5(10):1031-44
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of estrogen antagonists and aromatase inhibitors in breast cancer and hormonally sensitive tumors of the uterine body.
  • The new anti-estrogens, including the selective estrogen receptor modulators (e.g., toremifene, droloxifene, idoxifene, raloxifene and arzoxifene), the selective estrogen receptor downregulators (e.g., fulvestrant), and the new steroidal (e.g., exemestane) and non-steroidal (anastrozole and letrozole) aromatase inhibitors have been investigated in the treatment of breast cancer and hormonally sensitive tumors of the uterine body.
  • In postmenopausal women, anastrozole, letrozole and exemestane appear to have superior efficacy and an improved toxicity profile than tamoxifen, and fulvestrant seems to be at least as effective as anastrozole in patients in whom tumors have progressed after prior endocrine treatment.
  • Preliminary data showed a high response rate and a favorable toxicity profile for arzoxifene in endometrial cancer, whereas letrozole could represent a new interesting therapeutic tool for endometrial cancer as well as for low-grade endometrial stromal sarcoma.
  • [MeSH-major] Aromatase Inhibitors / therapeutic use. Breast Neoplasms / drug therapy. Estrogen Antagonists / therapeutic use. Neoplasms, Hormone-Dependent / drug therapy. Uterine Neoplasms / drug therapy
  • [MeSH-minor] Cell Line, Tumor. Cell Survival / drug effects. Clinical Trials as Topic. Female. Humans

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15535424.001).
  • [ISSN] 1472-4472
  • [Journal-full-title] Current opinion in investigational drugs (London, England : 2000)
  • [ISO-abbreviation] Curr Opin Investig Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aromatase Inhibitors; 0 / Estrogen Antagonists
  • [Number-of-references] 161
  •  go-up   go-down


22. Ruiz Tovar J, Reguero Callejas ME, Arano Bermejo JI, Capote Armas LF, González-Palacios Martínez F, Cabañas Navarro L: Malignant mixed Mullerian tumors. Clin Transl Oncol; 2006 Feb;8(2):129-32
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MMMTs derive from the mullerian mesodermus that differentiates in epithelial and stromal elements, both malignant elements.
  • Treatment in 2 patients was hysterectomy with double ooforectomy, and resection of the pelvic mass was the treatment in the third case.
  • Adjuvant radio chemotherapy was administrated in 2 of the 3 cases.
  • Follow-up revealed recurrent pelvic tumour in 1 patient at 59 months, and breast metastases at 20 months in the second one.
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / secondary. Breast Neoplasms / secondary. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Fatal Outcome. Female. Femoral Neoplasms / secondary. Humans. Hysterectomy. Ifosfamide / administration & dosage. Ilium. Middle Aged. Neoplasms, Second Primary. Ovariectomy. Paclitaxel / administration & dosage. Palliative Care. Pelvic Neoplasms / secondary. Pelvic Neoplasms / surgery. Prognosis. Radiotherapy, Adjuvant. Sarcoma, Ewing. Spinal Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chirurgie. 1996;121(3):198-202 [8945826.001]
  • [Cites] J Obstet Gynaecol. 2003 May;23(3):301-3 [12850867.001]
  • [Cites] Br J Obstet Gynaecol. 1983 Jun;90(6):562-9 [6305395.001]
  • [Cites] J Clin Pathol. 2002 May;55(5):321-5 [11986333.001]
  • [Cites] Cancer. 1996 Feb 15;77(4):717-24 [8616764.001]
  • [Cites] Int J Gynecol Cancer. 2002 Nov-Dec;12(6):687-90 [12445244.001]
  • (PMID = 16632428.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


23. Giordano G, Lombardi M, Brigati F, Mancini C, Silini EM: Clinicopathologic features of 2 new cases of uterine tumors resembling ovarian sex cord tumors. Int J Gynecol Pathol; 2010 Sep;29(5):459-67
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Uterine neoplasms showing an exclusive sex cord-like differentiation or focal low-grade sarcoma differentiation, designated as uterine tumors resembling ovarian sex cord tumors (UTROSCTs), are rare, with only 48 cases described earlier in international literature.
  • In these examples, the pathologic diagnosis of UTROSCT was made incidentally after the clinical diagnosis of a leiomyoma and endometrial polyp.
  • On examination of small biopsies, the diagnosis was facilitated by specific immunohistochemical analysis using markers for the sex cord component.
  • In the other case, the neoplasm seemed to be the consequence of tamoxifen treatment for breast carcinoma.
  • After diagnosis, in this second case, the woman underwent hysterectomy that showed a residue of the tumor and cervical metastasis from the earlier breast carcinoma.
  • The differential diagnosis of UTROSCT and the role of immunohistochemistry in confirming a diagnosis are discussed.
  • [MeSH-minor] Adult. Antineoplastic Agents, Hormonal / adverse effects. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Carcinoma, Lobular / secondary. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasms, Second Primary / pathology. Ovarian Neoplasms / pathology. Sex Cord-Gonadal Stromal Tumors / pathology. Tamoxifen / adverse effects. Uterine Cervical Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20736772.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


24. Miettinen M: From morphological to molecular diagnosis of soft tissue tumors. Adv Exp Med Biol; 2006;587:99-113
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] From morphological to molecular diagnosis of soft tissue tumors.
  • Cytogenetic discoveries of balanced translocations in soft tissue tumors have opened the way to molecular genetic definition of these translocations as gene fusions from the late 1980s.
  • Many sarcomas are known to have such fusions, and the demonstration of the fusion transcripts in tumor tissue is of great value in specific diagnosis of synovial sarcoma (SYT-SSX), Ewing sarcoma (EWS-Fli1), clear cell sarcoma (EWS-ATF1), myxoid liposarcoma (FUS-CHOP), and other sarcomas.
  • Demonstration of SYT-SSX and EWS-ATF1 fusion assists in the diagnosis of synovial and clear cell sarcomas in unusual locations, such as the gastrointestinal tract, where these tumors occur with low frequency.
  • Demonstration of sarcoma translocations and their fusion by different assays is well established; use of in situ hybridization is limited by availability of specific probes.
  • In two exceptional instances, the same translocation and gene fusion occurs in two unrelated diseases: ETV6-NTRK fusion in infantile fibrosarcoma and secretory carcinoma of the breast, and ALK-TPM3 fusion in inflammatory myofibroblastic tumor and large cell anaplastic lymphoma.
  • Activating mutations in two related receptor tyrosine kinases (RTKs), KIT, and platelet-derived growth factor receptor alpha (PDGFRA) is central to the pathogenesis of gastrointestinal stromal tumors (GISTs), and countering the mutational activation by specific tyrosine kinase inhibitors, such as Imatinib mesylate, is now standard treatment for metastatic GISTs.
  • Mutation type influences therapy responsiveness, but fortunately very few GISTs carry primarily Imatinib-resistant mutations.
  • Secondary drug resistance acquired during Imatinib treatment based on new, Imatinib-resistant mutations is a major problem limiting treatment success.
  • Schwannoma types may differ in their pathogenesis: gastrointestinal schwannomas lack NF2 changes suggesting a different pathogenesis.
  • Specific viral sequences of human herpesvirus 8 (HHV8) are diagnostic markers for Kaposi sarcoma (KS), and are absent in angiosarcoma.
  • [MeSH-major] Genetic Testing. Soft Tissue Neoplasms / genetics. Soft Tissue Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Genetic Testing.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17163160.001).
  • [ISSN] 0065-2598
  • [Journal-full-title] Advances in experimental medicine and biology
  • [ISO-abbreviation] Adv. Exp. Med. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 70
  •  go-up   go-down






Advertisement